Eikon Therapeutics, Inc.

NasdaqGS:EIKN Stock Report

Market Cap: US$678.9m

Eikon Therapeutics Management

Management criteria checks 1/4

Eikon Therapeutics' CEO is Roger Perlmutter, appointed in May 2021, has a tenure of 5.17 years. total yearly compensation is $12.95M, comprised of 4.4% salary and 95.6% bonuses, including company stock and options. directly owns 2.73% of the company’s shares, worth $18.51M. The average tenure of the management team and the board of directors is 5.1 years and 2.6 years respectively.

Key information

Roger Perlmutter

Chief executive officer

US$12.9m

Total compensation

CEO salary percentage4.43%
CEO tenure5.2yrs
CEO ownership2.7%
Management average tenure5.1yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 12

Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating

Summary Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a robust oncology-focused pipeline. EIKN’s ASCO data for EIK1001 in NSCLC showed a 63.1% ORR and favorable safety, but the market response was muted. Cash reserves of $596m provide a runway into 2027 despite high R&D burn; valuation is now below cash, reflecting skepticism. Future catalysts include maturing clinical data, strategic board appointments, and potential for additional pipeline advancements. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Roger Perlmutter's remuneration changed compared to Eikon Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$342m

Dec 31 2025US$13mUS$574k

-US$334m

Sep 30 2025n/an/a

-US$319m

Dec 31 2024US$803kUS$563k

-US$244m

Compensation vs Market: Roger's total compensation ($USD12.95M) is above average for companies of similar size in the US market ($USD3.54M).

Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.

CEO

Roger Perlmutter (74 yo)

5.2yrs
Tenure
US$12,946,682
Compensation

Dr. Roger M. Perlmutter, Ph D., M.D., is Director of NGM Bio Holdings, Inc. Dr. Perlmutter serves as Independent Director at NGM Biopharmaceuticals, Inc. since June 8, 2021. Dr. Perlmutter serves as Member...

Leadership Team

NamePositionTenureCompensationOwnership
Roger Perlmutter
Chairman5.2yrsUS$12.95m2.73%
$ 18.5m
Michael Klobuchar
Chief Operating Officer1.7yrsUS$2.02m0%
$ 0
Roy Baynes
Executive VP & Chief Medical Officer4yrsUS$1.61m0%
$ 0
Robert Tjian
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Eric Betzig
Co-Founder & Member of Scientific Advisory Board7yrsno datano data
Alfred Bowie
Treasurer & CFO5.1yrsno data0.095%
$ 646.7k
Russ Berman
Chief Technology Officerno datano datano data
Benjamin Thorner
Secretary5.5yrsno datano data
Barbara Howes
Chief People Officerno datano datano data
5.1yrs
Average Tenure
61yo
Average Age

Experienced Management: EIKN's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roger Perlmutter
Chairman5.2yrsUS$12.95m2.73%
$ 18.5m
Robert Tjian
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Eric Betzig
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Kenneth Frazier
Independent Director4.3yrsUS$68.00k0%
$ 0
Josh Wolfe
Director4.5yrsno datano data
Thomas Cech
Member of Scientific Advisory Boardno datano datano data
David Meline
Independent Directorless than a yearUS$1.23m0%
$ 0
Leon Chen
Director7.5yrsno datano data
Robert Huffines
Independent Director2.6yrsUS$70.93k0%
$ 0
Trey Ideker
Member of Scientific Advisory Board2.5yrsno datano data
Wendy Young
Member of Scientific Advisory Board2.5yrsno datano data
Fatima Francisco
Independent Directorless than a yearno datano data
2.6yrs
Average Tenure
69yo
Average Age

Experienced Board: EIKN's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:38
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eikon Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Imogen MansfieldCantor Fitzgerald & Co.
Lut Ming ChengJ.P. Morgan